EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark e-therapeutics was filed as Word mark on 07/05/2022 at the European Union Intellectual Property Office.
It was registered as a trademark on 03/16/2023.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 018728291 |
| Application date | July 5, 2022 |
| Publication date | December 7, 2022 |
| Entry date | March 16, 2023 |
| Expiration date | July 5, 2032 |
Trademark owner
4 Kingdom Street
W2 6BD London
GB
W2 6BD London
GB
Trademark representatives
Varso Tower Chmielna 69
00-801 Warsaw
PL
goods and services
5
Pharmaceutical and medical preparations; pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals; short interfering RNA (siRNA) medicines and pharmaceuticals; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; none of the aforementioned goods for, or related to, T-cells or T-cell receptors
9
Computer software for use in the field of pharmaceuticals, medicines and drug discovery; artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery; electronic databases for use in the field of pharmaceuticals, medicines and drug discovery; computer platform software platforms for use in the field of pharmaceuticals, medicines and drug discovery; computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery; none of the aforementioned goods for, or related to, T-cells or T-cell receptors
40
Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid; none of the aforementioned services for, or related to, T-cells or T-cell receptors
42
Pharmaceutical research and development services; scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acidbased drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; genetic research; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAibased medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in relation to RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning in relation to RNAibased medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid; none of the aforementioned services for, or related to, T-cells or T-cell receptors
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| October 30, 2024 | Change Representative, Published | ||
| October 3, 2024 | RAW: Trade mark - Partial Surrender, Published |
ID: 11018728291